Biotron Limited · ASX:BIT
Biotron — Investor Presentation (October 2020)
10 slides from Biotron's investor presentation, October 2020
Slide 1: Biotron Limited Investor Update October 2020
BIOTRON LIMITED (ASX:BIT) Investor Update October 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 3: Biotron Overview
Biotron Overview • Clinical stage company developing small molecule drugs targeting big health problems: • HIV‐1, Hepatitis B, COVID‐19, Dengue and others • Positive data in trials to date including a successful HIV‐1 Phase 2 trial • Potential for improved health outcomes and eradication of reservoi
Slide 4: Key Achievements in Last 12 Months
Key Achievements in Last 12 Months • Raised $5.8 million in Dec 2019 from exercise of BITOB options • Reported positive results from the Phase 2 HIV‐1 clinical trial of BIT225 • Set up world‐class Advisory Board of international HIV‐1 experts • Appointed US‐based Chief Medical Officer • Presented ke
Slide 5: SARS-CoV-2
SARS‐CoV‐2 • Biotron’s core expertise is designing drugs to target a key viral protein found on a range of different viruses • Biotron researchers were first to identify and report on this protein (E protein) on coronaviruses (Refer Wilson et al, Virology 353 (2006):294‐306) • Designed compounds tar
Slide 6: HIV-1 Eradication
HIV‐1 Eradication Why is HIV‐1 eradication necessary? • Current antiretroviral drugs (ART) do not eradicate the virus • Long‐term health implications eg. HAND, immune activation, increase in malignancies and chronic diseases, drug‐drug interactions • Major burden on healthcare systems Consequences i
Slide 7: Significance of Results from BIT225 Phase 2 Trial
Significance of Results from BIT225 Phase 2 Trial • BIT225, a small molecule drug, combines direct‐acting antiviral activity with immune modulatory effects • This is a unique mode of action; no other antiviral drug combines these two treatment paradigms • BIT225 targets a key virus protein (Vpu) who
Slide 8: Outlook for 2020/2021 FY
Outlook for 2020/2021 FY • HIV‐1 program is the prime focus • Conferring with KOLs/advisory group to map out late‐stage clinical development • Progressing discussions with potential partners • Continuing screening to identify lead anti‐SARS‐CoV‐2 compound(s) to progress to next stage of development
Slide 9: Financial Information
Financial Information Key Financial Metrics Ticker Code ASX: BIT Share Price (13/10/2020) A $0.105 Market Cap A $70 million 12 Month Trading Range A $0.05 – 0.185 Shares Outstanding 702 million Cash Position (09/2020) A $7.66 million Board Michael Hoy Non‐executive Chairman Michelle Miller Managing
Slide 10: Biotron Limited (ASX:BIT)
BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au